Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607841 | 0.89 | KDM4E (0.43) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6629036 | 0.88 | KDM4E (0.46) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6606995 | 0.85 | KMT2A (0.37) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6628855 | 0.84 | KDM4E (0.42) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6802290 | 0.83 | ADORA1 (0.37) | KDM4EKMT2AMEN1PKMMAPT | |
| SCHEMBL6616088 | 0.80 | KDM4E (0.45) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6604916 | 0.80 | ADORA1 (0.38) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6601292 | 0.78 | KDM4E (0.44) | KDM4ETDP1KMT2AMEN1PKM | |
| SCHEMBL6606018 | 0.78 | KDM4E (0.43) | KDM4ETDP1PKMMAPTL3MBTL1 | |
| SCHEMBL6603662 | 0.78 | ICMT (0.41) | MAPTL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-1432689-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027074-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | KDM4E 3990/4885TDP1 608/4885KMT2A 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.